Replimune Group Inc
Company Profile
Business description
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Contact
500 Unicorn Park Drive
Suite 303, 3rd Floor
WoburnMA01801
USAT: +1 781 222-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
479
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,779.30 | 4.50 | 0.05% |
| CAC 40 | 7,615.99 | 78.42 | 1.04% |
| DAX 40 | 23,641.58 | 372.57 | 1.60% |
| Dow JONES (US) | 43,089.02 | 507.24 | 1.19% |
| FTSE 100 | 8,758.99 | 0.95 | 0.01% |
| HKSE | 24,371.11 | 194.04 | 0.80% |
| NASDAQ | 19,912.53 | 281.56 | 1.43% |
| Nikkei 225 | 38,791.18 | 0.62 | 0.00% |
| NZX 50 Index | 12,446.05 | 21.43 | -0.17% |
| S&P 500 | 6,092.18 | 67.01 | 1.11% |
| S&P/ASX 200 | 8,559.80 | 4.30 | 0.05% |
| SSE Composite Index | 3,430.16 | 9.60 | 0.28% |